A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 248 participants.

Also called NCT04515849

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 248 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04515849
  • EudraCT 2020-000255-12
Other papers using this trial's data
  • A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease Kidney international, 2024-12 DOI, PubMed 39218393

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Australia, Canada, Germany, Japan, New Zealand, Poland, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04515849. Randomized; double masking; primary purpose treatment. Start 2020-08-31 (actual); primary completion 2022-03-08 (actual). Results posted on 2025-01-17.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Condition
Chronic Kidney Diseases
Intervention (Drug)
Cotadutide 100 micrograms
Intervention (Drug)
Cotadutide 300 micrograms
Intervention (Drug)
Cotadutide 600 micrograms
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct04515849
Content hash
9542a940dcc736b8491b14b2c9074104d018f33c7c9b6e0807e8bd5b74a56ee2